Trial reportClinical journal of the American Society of Nephrology : CJASN2020
Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03257410 (A Multi-Center, Prospective, Randomized, Controlled, Open-label, Parallel Study to Evaluate the Safety and Efficacy of the Theranova 400 Dialyzer In End Stage Renal Disease), which is not on this map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Prospective, Randomized, Controlled, Open-label, Parallel Study to Evaluate the Safety and Efficacy of the Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Comparative efficacy of expanded hemodialysis and online hemodiafiltration: a systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- Efficacy and safety of expanded hemodialysis in hemodialysis patients: a meta-analysis and systematic review.Renal failure · 2022Pooled it
- Efficacy of medium cut-off dialyzers and comparison with high-flux dialyzers in patients on maintenance hemodialysis: A systematic review and meta-analysis.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2022Pooled it
- Comparison of middle molecule removal with expanded hemodialysis versus haemodiafiltration among Chinese hemodialysis patients.Renal failure · 2025Trial
- A randomized prospective cross over study on the effects of medium cut-off membranes on T cellular and serologic immune phenotypes in hemodialysis.Scientific reports · 2022Trial
- Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States.Hemodialysis international. International Symposium on Home Hemodialysis · 2022Trial
- Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial.Scientific reports · 2021Trial
- Performance-based classification of dialyzers: integrating YKL-40 for advanced middle-molecule clearance - A Chinese expert consensus.Renal failure · 2026Review
- Budget impact of expanded hemodialysis versus high-flux hemodialysis using real-world evidence in Colombia.Cost effectiveness and resource allocation : C/E · 2026Article
- Expanded Hemodialysis Using a Medium Cut-Off Dialyzer for Severe Valproic Acid Poisoning: A Case Report with Real-Time Therapeutic Drug Monitoring.Journal of clinical medicine · 2026Article
- Article
- Expanded Hemodialysis with Theranova 500 Improves Dialysis Adequacy and Blunts Inflammation: A 24-Week Quasi-Randomized Trial.Journal of clinical medicine · 2025Article
- Impact of Expanded Hemodialysis on Subjective Experience Using Dynamic Patient-Reported Outcome Measurement Tool.Kidney medicine · 2025Article
- Increasing the Removal of Large Solutes by Kidney Replacement Therapy.Journal of the American Society of Nephrology : JASN · 2025Review
- Assessment of Safety and Efficacy of Expanded Hemodialysis with Medium Cut-Off Dialyzer Compared to Haemodiafiltration.Journal of clinical medicine · 2025Article
- Expanded Hemodialysis with Theranova Dialyzer and Residual Kidney Function in Patients Starting Long-Term Hemodialysis: A Randomized Controlled Trial.Journal of the American Society of Nephrology : JASN · 2025Article
- Efficacy in the reduction ratios of middle molecules with the use of medium cut-off dialyzers and reduced dialysate flows: a cohort study.Frontiers in medicine · 2025Article
- Survival Differences in Patients with High-Flux Hemodialysis versus Expanded Hemodialysis: A Cohort Study.Blood purification · 2025Article
- Twice Weekly versus Thrice Weekly Hemodialysis-A Pilot Cross-Over Equivalence Trial.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- The ADVanced Organ Support (ADVOS) hemodialysis system removes IL-6: an in vitro proof-of-concept study.Intensive care medicine experimental · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesExpanded hemodialysis therapy enabled by medium cut-off membranes may promote greater clearance of larger middle molecules that comprise putative uremic solutes than conventional high-flux dialysis. This randomized trial evaluated the efficacy and safety of hemodialysis treatment with a medium cut-off dialyzer. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Clinically stable patients on maintenance hemodialysis were randomized to receive dialysis with either a medium cut-off dialyzer (Theranova 400) or a high-flux dialyzer (Elisio-17H) over 24 weeks of treatment. The primary safety end point was the predialysis serum albumin level after 24 weeks of treatment. The primary efficacy end point was the reduction ratio of free
resultsAmong 172 patients on maintenance hemodialysis, mean age was 59±13 years, 61% were men, 40% were Black, and mean dialysis vintage was 5±4 years. Of the 86 patients randomized to each dialyzer, 65 completed the trial in each group. The reduction ratio for the removal of free
conclusionsHemodialysis therapy with the Theranova 400 dialyzer provides superior removal of larger middle molecules, as exemplified by free CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Multi-Center, Prospective, Randomized, Controlled, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of the Theranova 400 Dialyzer in End Stage Renal Disease (ESRD) Patients, NCT03257410.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.